regeneron eylea dupix hit coronaviru
updat forecast estim apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim apr
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
regeneron leverag monoclon antibodi research
develop platform becom one biotech
success emerg profit commerci oper
establish narrow moat lead drug eylea global sale north
billion annual approv wet age-rel macular
degener eye-rel indic drug remain
well posit dose potenti high-dos
formul allow continu hold strong market share
lucenti avastin novarti beovu
sale eylea grown double-digit pace sale outsid
unit state ramp usag new indic like
diabet macular edema took hold posit data larger
diabet retinopathi popul provid anoth boost
expect price pressur competit novarti beovu approv
late push eylea single-digit growth
patent expir within sanofi antibodi
collabor cholesterol reduct drug praluent
demonstr impress clinic result seen slow launch
trajectori payer restrict neg litig
outcom repatha howev immunolog drug
dupix see strong launch atop dermat
asthma approv continu expend new indic
nasal polyposi broader patient group younger dermat
patient lead potenti billion peak sale
also part sanofi collabor kevzara rheumatoid arthriti
launch libtayo oncolog drug
gain share nich partnership sanofi
new pipelin product scale back give
bispecif antibodi despit competit think
regeneron divers pipelin scientif leadership
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
regeneron pharmaceut discov develop commerci
product fight eye diseas cardiovascular diseas cancer
inflamm compani six market product eylea approv
wet age-rel macular degener eye diseas praluent
cholesterol lower zaltrap colorect cancer dupix atop
dermat asthma nasal polyposi libtayo cutan squamou
cell carcinoma arcalyst cap kevzara rheumatoid arthriti
regeneron also develop monoclon antibodi sanofi
immunolog cancer
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
rais fair valu estim regeneron
ad coronaviru target antibodi
program valuat model regeneron hope
human test earli summer drug could use
prevent treatment hundr thousand
prophylact dose could made end summer
assum probabl approv roughli
billion annual sale antibodi two-year
period antibodi could use prophylaxi
healthcar worker high-risk individu
also maintain kevzara sale estim think
arthriti drug could serv treatment patient
sever case price much lower less
patient requir one dose versu dose
year arthriti patient lower estim
cholesterol-low drug praluent immunolog drug
dupix ophthalmolog drug eylea expect
fewer new patient start praluent dupix
treatment delay eylea high-risk patient avoid
physician offic level throughout
major regeneron fair valu estim driven
expect eylea dupix franchis
think eylea could see world-wide peak sale billion
continu grow intern market despit
slower growth potenti biosimilar
includ milion potenti peak sale eylea
model patient prolif nonprolif
diabet retinopathi think praluent achiev sale
billion sale acceler follow
recent price negoti addit cardiovascular
outcom data label assum dupix
sale peak billion expect rapid uptak
strong long-term competit atop dermat
asthma firm dozen compound
clinic develop seen promis result
compound outsid lead drug estim
bispecif antibodi program par
estim similar roch program includ
probabl approv overal probability-weight
sale estim yield compound annual growth
firm next five year assum cost
equiti assum long-term tax rate regeneron
assign regeneron medium uncertainti rate
firm futur sale well diversifi sever
multi-billion-dollar product launch revenu today
still depend heavili eylea believ
regeneron fair valu per share examin two
addit scenario bull case assum stronger
sale praluent usag cholesterol-low drug
expand rapidli approv signific
develop market cost lead fair valu
estim per share bear case assum
praluent sale remain limit payer
restrict signific price cut failur
addit drug price headwind begin
due potenti drug price reform
develop market cost continu ramp
significantli regeneron expand pipelin lead
fair valu estim per share
leverag
assign narrow moat regeneron base
intang asset underli commerci potenti
eylea pipelin drug except product
monoclon antibodi mab research
develop platform expect regeneron eylea
achiev billion peak sale given strong competit
posit due attract dose regimen versu
lucentis/avastin ophthalmolog indic addit
regeneron promis product blockbust
potenti includ praluent alirocumab cholesterol
lower kevzara rheumatoid arthriti dupix
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
antibodi contain nonhuman compon
typic mice firm proprietari trap
velocisuit technolog platform includ velocimmun
protect patent well
signific accumul scientif technic expertis
sever clinic commerci success despit recent
setback eye diseas pipelin firm achiev
sustain profit larg due revenu eylea
expect sale dupix drive close billion
annual long run provid ad
resourc fund pipelin opportun
product firm strength discoveri
platform evid sever in-hous program
either part sanofi collabor fulli own
furthermor attract term sanofi deal
wherebi sanofi respons up-front develop
cost posit phase result obtain
allow regeneron minim cash burn shift
develop risk partner undertak larger
develop program advanc pipelin
candid would like feasibl otherwis
atop dermat asthma nasal polyp copd allerg
indic demonstr compani abil
intern develop success commerci drug
compani also extrem full earlier-stag
pipelin mab research partnership sanofi
support provid regeneron signific
financi support notabl strateg advantag beyond
patent protect market product
eylea dupix regeneron market
pipelin product biolog provid ad
defens gener competit due complex
cost manufactur biosimilar
attract partnership term regeneron abl
obtain sanofi other larg deriv
scientif leadership develop fulli human
monoclon antibodi use proprietari velocimmun
platform platform advantag lie primarili
speed effici produc fulli human
antibodi prefer due specif
tight bind therapeut target well
reduc risk potenti immun respons common
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oeylea becom lead franchis wet
ophthalmolog market
similar efficaci conveni dose regimen
compar lucenti avastin
odupix launch novel treatment patient
sever atop dermat asthma
benefit could extend sever allergy-rel
indic copd
oposit earli data bispecif antibodi
support potenti regeneron in-hous
oregeneron eylea compet roch
novarti ophthalmolog market eylea could
vulner biosimilar begin
owhil regeneron praluent enter multi-
billion-dollar cholesterol-low market face
litig
odupix potenti could cut short approv
novel oral dermat drug upadacitinib
tezepelumab could effect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
regeneron end billion cash
market secur healthi cash balanc
signific product revenu eylea sale think
firm reach sustain profit
forese futur therefor along support
develop partner regeneron abl avoid
significantli dilut exist sharehold bring
addit pipelin candid market
regeneron near-term success appear assur
eylea blockbust sale still face strong
competit entrench player lucenti avastin
potenti new competit novarti market
also matur propos control medicar
cost could hit eylea sale inhibitor
program praluent regeneron race
first market promis class drug
howev question market potenti
drug given high cost subcutan dose
context conveni effect inexpens oral
cholesterol-low drug like statin mainstay
treatment confid agent
success lucr smaller market
statin ineffect heterozyg famili
hypercholesterolemia statin-intoler patient
massiv opportun uncontrol statin patient
requir addit price concess addit
compani face on-going patent litig amgen
intellectu properti drug
type lawsuit typic resolv negoti
settlement single-digit royalti payment regeneron
may face larger financi penalti found
infring patent although take comfort
regeneron robust pipelin road drug approv
fraught regulatori obstacl zaltrap troubl
cancer indic demonstr clinic success
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
guarante regeneron drug candid make
market go mani tried-and-tru
product doctor often slow convert new
therapi final regeneron reli significantli larger
partner sanofi develop fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
founder leonard schleifer led regeneron chief
execut sinc incept board
led roy vagelo serv chairman sinc
former ceo merck includ sever
season biotech pharma execut scientif
strategi sign
share
drug-develop market cost serv well
thu far think manag done solid job
follow state goal includ bring new
compound market rapidli fill pipelin behind
american fund growth fund amer
share
fund
share
fund
enthusiasm leadership team temper
primarili insid worth vote per share
common share worth vote per share therefor
despit own outstand share
regeneron manag control virtual class
share quarter vote right decemb
partner sanofi also own firm
outstand share lock-up period expir
decemb sanofi could choos sell stake
attempt outright acquisit although
recent
distanc praluent market regeneron
immuno-oncolog pipelin seem hint toward former
pleas manag signific
creation sharehold valu recent year believ
compens polici overli gener
total pay packag schleifer chief scientif
offic georg yancopoulo fell million
pay exceed million annual
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
defens natur healthcar firm offer
concern around global recess due coronaviru
disrupt weigh global market
defens natur healthcar hold rel
basi dont expect signific chang
healthcar moat rate may make downward
adjust valuat healthcar account
near-term challeng expect modest chang
rel recent stock price movement base case
call strong econom rebound follow
recess modest impact
healthcar valuat given defens natur
compani howev coronaviru pandem exert
sustain impact economi significantli higher
number patient unemploy uninsur
underinsur could reduc healthcar demand
greater extent expect govern effort reduc
near-term hit keep harder-hit industri
busi effect treatment emerg
near-term effect coronaviru expect critic
therapi crowd elect procedur new
product non-critical-car product fewer elect
procedur weigh devic maker servic
focus covid-specif case could reduc
profit health insur brand drug firm
alreadi focus specialti drug expect less impact
industri drug administ hospit could
still feel crowd coronaviru patient also
clinic develop timelin probabl face
delay due coronaviru disrupt like slow
new product launch addit coronaviru
impact credit market could weigh heavili
indebt compani hospit firm
compani recent complet major acquisit
outlook coronaviru global
economi well potenti new treatment
coronaviru pleas see
widespread diseas drug pipelin progress
outlook chang drug price polici
initi result super tuesday democrat primari
show increas support former vice presid biden
whose nomin would reduc likelihood signific
drug price polici chang line
expect dont expect major chang fair
valu estim moat rate drug biotech
industri base result continu view
industri under-valued averag
due partli excess concern around potenti major
drug polici chang note elect result
bigger impact healthcar insur servic
relief ralli health insur servic provid
drug side movement toward moder
democrat biden like mean minor drug polici
chang reduc chanc medicar
scenario champion biden key oppon sen
berni sander would like significantli reduc
drug price negoti power one-pay
system elect support shift toward biden
believ like chang drug price polici
reform center around senat bill prescript drug
price reduct act pdpra howev still believ
propos hold less chanc pass base
mix level support parti havent
includ passag bill model howev
pass estim aggreg hit brand
drug sale medicar inflat price cap part
redesign propos bill believ drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
biotech industri could adapt headwind
minor impact cash flow partli cost cut
increas volum base lower price mandat
bill importantli bill would limit out-of-pocket
payment patient medicar would like help
appeas demand lower drug price
potenti drug polici chang key element
esg analysi drug firm pleas see recent
healthcar observ esg risk affect moat
pharma morningstar
look fairli valu dupix competit loom
maintain fair valu estim
regeneron follow solid fourth quarter beat
expect although slightli increas sale
assumpt
immuno-oncolog drug libtayo
lymphoma drug candid ad new late-
stage drug pnh therapi pozelimab model
also rais oper expens assumpt long
run think market cost immunolog drug dupix
cholesterol-low therapi praluent higher
anticip research develop cost
grow pipelin expand regeneron
process restructur antibodi collabor
sanofi manag provid guidanc later
quarter howev think decis give
regeneron sole right praluent sanofi gain
sole right global kevzara ex-u praluent
simplifi collabor overal think dupix
regeneron ophthalmolog drug eylea support firm
narrow moat enthusiasm dupix temper
high number competitor see
addit data near term includ oral jak
upadacitinib abrocitinib
head-to-head data dupix lilli
lebrikizumab phase data atop dermat
amgen/astra tezepelumab data late asthma
regeneron announc earlier week work
 depart human servic
antibodi treat novel coronaviru
heel success partnership ebola treatment regn-
regeneron initi work barda mer
epidem experi coronaviru famili
could prove valuabl regeneron expect could
antibodi test month pleas
see feb coronaviru note link gilead
analysi coronaviru impact healthcar
eylea sale growth global fourth
quarter stronger expect give drug
growth billion full year eylea hold well
new competit novarti beovu
caution still earli launch expect
eylea grow slightli manag
cite market growth rate mid- high singl digit
eylea growth fade dupix growth becom
critic drug doubl sale
billion atop dermat asthma
lead approv indic develop eosinophil
esophag copd potenti allergi could
boost sale current assum billion peak sale
larg split dermat asthma
slightli rais sale estim libtayo
drug domin nich skin cancer indic
pois gain least small slice larger market libtayo
phase first-lin nsclc monotherapi versu
chemo regeneron plan file
preliminari data posit patient show orr
libtayo versu chemo similar
therapi interim surviv analysi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
avail
pipelin remain encourag
bispecif slightli increas sale
estim news firm move forward
earlier line test nhl combin
chemotherapi data bispecif
earli data come could help
determin whether firm place increasingli
competit market regeneron earlier-stag pipelin
costimulatori bispecif led psma drug
could way regeneron differenti
immuno-oncolog dose still ramp
clear see data program year
long run therapi could use combin
firm bispecif along test
sustainalyt esg risk methodolog
point opportun pharma/biotech jan
sustainalyt
own
collabor broaden deepen
esg analysi incorpor environment social
govern factor valuat analysi
pharma focus
materi esg issu social realm think
firm expos esg risk morningstar
conclud valuation-affect esg risk brand
drug firm center price risk larg litig
provid comprehens evalu support
mostli wide moat rate industri
price could test medicar part
biomarin global price strategi rare-diseas drug
well seriou natur condit limit futur
price litig risk despit high price tag
medicar exposur minim
also like sanofi
valuat esg risk johnson johnson eli lilli look
least compel us base litig risk
valuat look under-valued
detail analysi price litig issu
top pharma name
coverag see januari
healthcar observ esg risk affect moat
pharma morningstar
trump propos drug reimport look limit
potenti lower drug price dec
trump administr move allow drug import
canada look challeng implement
limit scope dont expect major chang
fair valu estim drug biotechnolog
industri view administr move driven
polit motiv anoth elect cycl draw
near rather major structur shift influenc drug
price continu view price power drug
strong central pillar support moat rate
larg drug biotechnolog compani
overal see under-valued name roch
biomarin lowest exposur esg-rel
strategi focu sever diseas lower price
pressur includ base case alreadi factor much
potenti headwind intern benchmark
import action propos
human servic juli propos rule
releas fda decemb dont view
plan major driver lower drug price think
implement chang would difficult
practic hard reconcil safeti provis
part feder track-and-trac system stop
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
counterfeit drug ensur enough drug-firm suppli low
price canada anoth concern drug firm could
limit distribut limit re-import also canada would
like support plan low drug price would
like face rise pressur support price
implement scope drug target potenti
re-import limit exclud drug biolog
inject drug drug subject fda risk evalu
mitig strategi rem drug group repres
core area focu new drug reach market
congress support drug re-import past
safe implement propos limit
enact expect similar limit around
recent propos given complex distribut
differ drug label countri see poor
prospect wide use drug re-import
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
slightli boost regeneron fve follow
strong oncolog pipelin progress
regeneron third-quart result slightli better
anticip larg stronger
intern sale key ophthalmolog drug eylea
partli counter slower dupix growth bullish
expect model continu expect
moder single-digit eylea growth new competit
novarti beovu intensifi also expect
dupix drive grow profit firm
collabor sanofi come year drug
launch addit indic updat firm
oncolog pipelin progress encourag regeneron
bring bispecif antibodi program clinic
trial increas estim
regeneron bispecif test
lymphoma put par estim roch
similar program includ probabl approv
expect see data annual meet
american societi hematolog decemb could
increas expect regeneron bispecif
pipelin particularli firm bcma bispecif show
strong efficaci conveni administr schedul
also includ regeneron billion share
repurchas program model think
conduct under-valued level increas fair
valu estim overal push fair valu estim
per share per share firm
massiv eylea franchis strong dupix launch
grow oncolog pipelin potenti continu support
gain share
dive quarter result sale eylea
grew nearli billion third quarter
vegf
ophthalmolog market dupix global sale record
partner sanofi reach million slightli lower
expect still grow rapidli drug
penetr atop dermat market launch
asthma nasal polyposi market regeneron plan
file approv dupix younger atop dermat
patient age year-end move dupix
indic howev sanofi allianc product
cholesterol drug praluent immunolog drug kevzara --
launch slowli like drag
posit profit commerci partnership
regeneron sanofi work contain commerci
multipl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
cost program turn sanofi immuno-
oncolog partnership launch cancer drug libtayo
nich skin indic go well phase trial lung
cancer also proceed expect interim overal
surviv data expect libtayo monotherapi
patient libtayo potenti see
efficaci surpass current
antibodi like merck keytruda roch tecentriq
think prematur assum firm abl
differenti gain traction broader market
late entrant enthusiast
firm bispecif antibodi pipelin see
signific upsid model sale program
beyond still earli stage
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
